QPS will exhibit at the World Vaccine Congress, April 15-17 in Washington, DC. Please stop by our booth #600 to learn more about QPS’ capabilities in vaccine trials. Find out more at Vaccines or email: [email protected]
BREXIT IMPACT: More Questions Than Answers
Later this month the United Kingdom (UK) is expected to achieve independence from the European Union (EU) based on a referendum that was passed in June 2016. Yet Britain’s exit, or “Brexit,” leaves us with more questions than answers right now. We have been watching and waiting, with clarity expected on March 29, 2019, the …
QPS is exhibiting at the 13th Annual WRIB Meeting
QPS is exhibiting at the 13th Annual WRIB Meeting, April 1-4 in New Orleans, LA. If you are attending, please visit us at booth #49. Contact us at [email protected] for additional information.
QPS will exhibit at the 14th International Conference on Alzheimer’s & Parkinson’s Disease
QPS will exhibit at the 14th International Conference on Alzheimer’s & Parkinson’s Disease, March 26-31 in Lisbon, Portugal. Please stop by our booth #28 to learn more about QPS’ contract research services. Find out more at qpsneuro.com or email [email protected]
QPS is exhibiting at the 3rd Annual Gene Therapy for Rare Disorders Conference
QPS is exhibiting at the 3rd Annual Gene Therapy for Rare Disorders Conference, between March 26-28 in Boston, MA. If you are attending the meeting, please visit us to learn more about QPS’ range of services. We have supported gene therapy since 2002: ASOs, siRNAs, miRNA through mRNAs and viral vectors utilizing LC-HRMS, hybridization-LC, and …
QPS will exhibit at the 4th Annual Neuroscience R&D Technologies Conference, October 4-5 in Munich, Germany.
QPS will exhibit at the 4th Annual Neuroscience R&D Technologies Conference, October 4-5 in Munich, Germany. Please stop by our Booth #5 to learn more about QPS’ contract research services. Find out more at qpsneuro.com or email [email protected] #NeuroRnD #QPSLLC #CRO
Spreading Early Clinical Knowledge
Shoulder to shoulder with our clients, we at QPS like to share the results of our early clinical research efforts, published in the scientific literature. Learn more by reading: A Phase 1, Single-center, Double-blind, Placebo-controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Clinical Effects, and Pharmacokinetics-Pharmacodynamics of Intravenous Cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a Single …
Translational Medicine Now Bigger and Better at QPS
Goodbye boutique CRO, hello large study BIG PLAYER! For a long time, you’ve known us as THE high quality outfit that can stabilize difficult assays in the initial stages of clinical investigation. But we’ve been investing in additional technical personnel and laboratory capacity for translational medicine at our Flagship Delaware Technology Park facility. And now …
QPS’ Paul Lehman to Speak at Transdermal & Intradermal Drug Delivery Conference
The 2017 Transdermal & Intradermal Drug Delivery Systems conference covering Advanced Design, Development & Delivery of Skin-Mediated Therapies and Vaccines is coming up on September 28-29 at the venerable Racquet Club of Philadelphia. Don’t miss Paul Lehman, VP and Head of Dermal & Transdermal Research Services at QPS, presenting “Evolution of the In Vitro Permeation …
QPS Tapped for Two New FIH Studies
Two companies have just selected QPS Netherlands to conduct their First-in-Human studies. Acticor Biotech, a Paris-based biotechnology company focused on the treatment of acute ischemic stroke, selected the QPS facility in Groningen, The Netherlands, to manage a Phase I clinical study. The goal of the study is to assess safety and tolerance as well as …
